×
Back to Agenda
Misconduct and Management of Serious or Continued Noncompliance: Differences, Similarities, and Building a World-Class Program
Session Chair(s)
Deborah A. Waltz, MS
Vice President, Global Compound Support, Quality Assurance, Takeda Pharmaceuticals International, Inc., United States
Risk-Based Monitoring and Fraud Detection in Clinical Trials
Learning Objective : Discuss current FDA compliance expectations for sponsors and investigators; Identify and differentiate between manageable/correctable noncompliance and serious or continued noncompliance and scientific misconduct; Provide strategies for appropriate management and escalation techniques.
Speaker(s)
Richard Zink
Principal Research Fellow, JMP Statistical Discovery, United States
Risk-Based Monitoring and Fraud Detection in Clinical Trials
Faranak Jamali, MD
Medical Officer, OSI, Office of Compliance, CDER, FDA, United States
Good Clinical Practices: A CDER Perspective
Have an account?